UNSPSC 51263163: Flestolol sulfate

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22FN3O4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T5MWT8445U, chemically known as o-fluorobenzoic acid, 3-ester with (+-)-(2-((2,3-dihydroxypropyl)amino)-2-methylpropyl)urea, sulfate (1:1) (salt) but more generally known as flestolol sulfate, which bears US NIH Compound Identifier 55884. Most nations, for tariff and trade purposes, schedule flestolol sulfate under HS 29242190 and SITC 51473.

As of Q4 2014, FLESTOLOL SULFATE remains US FDA's Preferred Term for this commodity. Flestolol sulfate bears US NLM identifiers UMLS ID C0956983 and NCI Concept Code C73017. SMILES: CC(C)(CNC(=O)N)NCC(COC(=O)C1CCCCC1F)O.OS(=O)(=O)O.

UNSPSC 51263163 Flestolol sulfate is a Commodity code that in recent state and local procurement activity does not reflect purchases of the pharmaceutical substance itself, but rather of naloxone and drug deactivation systems—distinct products that fall outside the nominal scope of this code. The recent opportunities tagged to this code show a significant mismatch: Seminole County, Florida's IFB for naloxone and safe drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription fulfillment, are pharmaceutical procurement activities that do not align with flestolol sulfate as a specific drug product. State and local governments appear to have applied this code incorrectly, or the tagging reflects a broader pharmaceutical-acquisition category that the code's specificity does not support.

The geographic activity centers on Florida and Texas, but the issuing bodies—a county health department and a state HHS agency—are soliciting for naloxone supplies and pharmacy benefit program structures rather than for flestolol sulfate. Seminole County's IFB (posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Texas HHS RFI (posted April 3, 2026) is exploratory, gathering vendor capabilities on direct-to-manufacturer prescription programs rather than soliciting a specific pharmaceutical product. The code shows little relevant recent activity aligned with flestolol sulfate procurement; the opportunities present suggest either miscoding in the source or use of this commodity code as a placeholder for broader pharmaceutical-acquisition categories that do not map cleanly to individual drug products.